Please use this identifier to cite or link to this item:
Title: Impact of SAfinamide on Depressive Symptoms in Parkinson's Disease Patients (SADness-PD Study): A Multicenter Retrospective Study.
Issue Date: 13-Feb-2021
Citation: Brain Sci.2021;(11)2:
Abstract: We aimed to assess the effects of safinamide on depression, motor symptoms, and the serotonin syndrome related to its co-administration with antidepressants in patients with Parkinson's disease (PD). We retrospectively analyzed the data of patients at 1 and 3 months of follow-up compared to baseline. n = 82 (safinamide 50 mg = 22, 100 mg = 60, with antidepressants = 44). First, we found improvement in depression (Hamilton Depression Rating Scale: -6 ± 5.10 at 1 month and -7.27 ± 5.10 at 3 months, p Safinamide could be useful for treating depression in PD; it was effective for motor symptoms and motor complications and safe even when co-administered with antidepressants.
PMID: 33668408
Rights: openAccess
ISSN: 2076-3425
Appears in Collections:Fundaciones e Institutos de Investigación > FIIB H. U. Infanta Sofía y H. U. Henares > Artículos

Files in This Item:
File SizeFormat 
PMC7918129.pdf700.2 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons